SCHEMBL23939769

SCHEMBL23939769

CNC(=O)c1nsnc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
ALDH1A1 P00352 5/20 0.58
HSD17B10 Q99714 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
YTHDC1 Q96MU7 1/20 0.36
CFTR P13569 1/20 0.35
MAPT P10636 3/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
THRB P10828 1/20 0.32
PIK3CD O00329 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CG P48736 2/20 0.31
HPGD P15428 3/20 0.31
ALOX15 P16050 2/20 0.31
PKM P14618 1/20 0.31
MEN1 O00255 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282494 0.77 YTHDC1 (0.37) KDM4EALDH1A1HSD17B10L3MBTL1YTHDC1
SCHEMBL4115514 0.75 KDM4E (0.49) KDM4EALDH1A1HSD17B10L3MBTL1CFTR
SCHEMBL2518142 0.73
SCHEMBL22207679 0.67 KMT2A (0.50) KDM4EALDH1A1L3MBTL1MAPTGAA
SCHEMBL1230868 0.67 PRKCI (0.56) KDM4ERAB9APIK3CDPKM
SCHEMBL7458435 0.65 ALDH1A1 (0.44) KDM4EALDH1A1HSD17B10L3MBTL1YTHDC1
SCHEMBL7454034 0.64 ALDH1A1 (0.37) KDM4EALDH1A1HSD17B10CFTRMAPT
SCHEMBL16636736 0.64 ALDH1A1 (0.44) KDM4EALDH1A1HSD17B10L3MBTL1CFTR
SCHEMBL18335840 0.64 CFTR (0.43) KDM4EALDH1A1HSD17B10YTHDC1CFTR
SCHEMBL18337793 0.64 CFTR (0.36) KDM4EYTHDC1CFTRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR PDE3B, PDE4A, PDE3A KDM4E 697/4885ALDH1A1 1476/4885HSD17B10 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.